Quick Answer
IDEAYA Biosciences, Inc. reported Total Revenue of $218.71 million for fiscal year 2025.
IDEAYA Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $218.71M +3024.4% |
$7.00M -70.1% |
$23.39M -54.1% |
$50.93M +82.3% |
$27.94M +43.0% |
$19.54M |
| Revenue (ASC 606) | $218.71M +3024.4% |
$7.00M -70.1% |
$23.39M -54.1% |
$50.93M +82.3% |
$27.94M +43.0% |
$19.54M |
| Net Income | -$113.70M +58.6% |
-$274.48M -143.0% |
-$112.96M -92.6% |
-$58.66M -17.9% |
-$49.76M -44.3% |
-$34.49M +17.8% |
| Diluted EPS | -$1.28 +61.9% |
-$3.36 -71.4% |
-$1.96 -38.0% |
-$1.42 -0.7% |
-$1.41 -0.7% |
-$1.40 |
| Total Assets | $1.11B -1.3% |
$1.12B +73.1% |
$649.32M +67.4% |
$387.97M +1.7% |
$381.35M +27.9% |
$298.27M +164.0% |
| Cash and Equivalents | $112.83M +33.7% |
$84.38M -46.3% |
$157.02M +128.8% |
$68.63M -25.4% |
$92.05M +27.8% |
$72.04M +111.5% |
| Stockholders Equity | $1.02B -3.4% |
$1.06B +70.5% |
$621.09M +77.7% |
$349.45M +15.9% |
$301.51M +52.1% |
$198.27M +97.5% |
| R&D Expense | $314.70M +6.8% |
$294.67M +127.5% |
$129.51M +44.6% |
$89.54M +54.0% |
$58.16M +46.5% |
$39.70M +15.7% |
| Operating Income | -$159.31M +51.3% |
-$326.98M -143.2% |
-$134.43M -115.1% |
-$62.50M -24.3% |
-$50.27M -42.2% |
-$35.34M +20.2% |
| Shares Outstanding | 87.80M +1.5% |
86.50M +33.0% |
65.04M +35.0% |
48.19M +25.1% |
38.53M +30.5% |
29.54M +45.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $207.83M | — | — |
| Revenue (ASC 606) | September 30, 2025 | $207.83M | — | — |
| Net Income | September 30, 2025 | $119.24M | +330.1% | +253.9% |
| Diluted EPS | September 30, 2025 | $1.33 | +321.7% | +251.1% |
| Total Assets | September 30, 2025 | $1.19B | -4.4% | +13.8% |
| Cash and Equivalents | September 30, 2025 | $298.93M | -25.3% | +160.7% |
| Stockholders Equity | September 30, 2025 | $1.09B | -7.5% | +13.8% |
| R&D Expense | September 30, 2025 | $82.99M | +45.2% | +11.8% |
| Operating Income | September 30, 2025 | $108.45M | +262.1% | +222.1% |
| Shares Outstanding | September 30, 2025 | 87.67M | +1.5% | +0.0% |
- IDEAYA Biosciences, Inc. reported Total Revenue of $218.71 million for fiscal year 2025.
- IDEAYA Biosciences, Inc. showed an increase of +3024.4% in Total Revenue compared to the prior fiscal year.
- IDEAYA Biosciences, Inc. reported Revenue (ASC 606) of $218.71 million for fiscal year 2025.
- IDEAYA Biosciences, Inc. showed an increase of +3024.4% in Revenue (ASC 606) compared to the prior fiscal year.
- IDEAYA Biosciences, Inc. reported Net Income of -$113.70 million for fiscal year 2025.
- IDEAYA Biosciences, Inc. showed an increase of +58.6% in Net Income compared to the prior fiscal year.
- IDEAYA Biosciences, Inc. reported Diluted EPS of $1.28 per share (loss) for fiscal year 2025.
- IDEAYA Biosciences, Inc. showed an increase of +61.9% in Diluted EPS compared to the prior fiscal year.
- IDEAYA Biosciences, Inc. reported Total Assets of $1.11 billion for fiscal year 2025.
- IDEAYA Biosciences, Inc. showed a decrease of -1.3% in Total Assets compared to the prior fiscal year.
- IDEAYA Biosciences, Inc. reported Cash and Equivalents of $112.83 million for fiscal year 2025.
- IDEAYA Biosciences, Inc. showed an increase of +33.7% in Cash and Equivalents compared to the prior fiscal year.
- IDEAYA Biosciences, Inc. reported Stockholders Equity of $1.02 billion for fiscal year 2025.
- IDEAYA Biosciences, Inc. showed a decrease of -3.4% in Stockholders Equity compared to the prior fiscal year.
- IDEAYA Biosciences, Inc. reported R&D Expense of $314.70 million for fiscal year 2025.
- IDEAYA Biosciences, Inc. showed an increase of +6.8% in R&D Expense compared to the prior fiscal year.
- IDEAYA Biosciences, Inc. reported Operating Income of -$159.31 million for fiscal year 2025.
- IDEAYA Biosciences, Inc. showed an increase of +51.3% in Operating Income compared to the prior fiscal year.
- IDEAYA Biosciences, Inc. reported Shares Outstanding of 87.80 million shares for fiscal year 2025.
- IDEAYA Biosciences, Inc. showed an increase of +1.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: